The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Abiraterone after docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients (p) in an off-protocol routine clinical setting.
Maria Ochoa de Olza
No relevant relationships to disclose
Albert Font
No relevant relationships to disclose
Nuria Sala
No relevant relationships to disclose
Miguel Beltran
No relevant relationships to disclose
Maria Pilar Barretina Ginesta
No relevant relationships to disclose
Olatz Etxaniz
No relevant relationships to disclose
Maria de los Llanos Gil
No relevant relationships to disclose
Xavier Garcia del Muro
No relevant relationships to disclose
Pamela Celiz
No relevant relationships to disclose
Jose R. Germa-Lluch
No relevant relationships to disclose